Radionuclide Imaging in Cardiac Amyloidosis: Are Nuclear Bone Tracers a Foreseeable Future?

详细信息    查看全文

• 作者：Sabahat Bokhari (1)
  Reehan Shahzad (1)
  Mathew Maurer (1)
  
  1. Department of Medicine ; Division of Cardiology ; NewYork Presbyterian Hospital/Columbia University Medical Center ; 622 West 168th Street ; PH 10-203 ; New York ; NY ; 10032 ; USA
  
• 关键词：Nuclear imaging ; Cardiac amyloidosis ; Transthyretin ; 123I ; MIBG ; 99mTc ; PYP ; 99mTc ; DPD ; [11] Other heart failure ; [32] Nuclear cardiology and ET ; [124] Cardiovascular imaging agents/techniques
• 刊名：Current Cardiovascular Imaging Reports
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：8
• 期：2
• 全文大小：473 KB
• 参考文献：1. Dharmarajan, K, Maurer, MS (2012) Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc 60: pp. 765-74 CrossRef
  2. Desai, HV, Aronow, WS, Peterson, SJ, Frishman, WH (2010) Cardiac amyloidosis: approaches to diagnosis and management. Cardiol Rev 18: pp. 1-11 CrossRef
  3. Dubrey, SW, Cha, K, Anderson, J, Chamarthi, B, Reisinger, J, Skinner, M (1998) The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91: pp. 141-57 CrossRef
  4. Sultan AM, Edwards WD, Mohammed SF, et al. Cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction. Circulation. 2010;122.
  5. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013.
  6. Cooper, LT, Baughman, KL, Feldman, AM (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116: pp. 2216-33 CrossRef
  7. Dubrey, SW, Cha, K, Skinner, M, LaValley, M, Falk, RH (1997) Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78: pp. 74-82 CrossRef
  8. Gertz, MA, Kyle, RA, Thibodeau, SN (1992) Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period. Mayo Clin Proc 67: pp. 428-40 CrossRef
  9. Ng, B, Connors, LH, Davidoff, R, Skinner, M, Falk, RH (2005) Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 165: pp. 1425-9 CrossRef
  10. Falk, RH, Dubrey, SW (2010) Amyloid heart disease. Prog Cardiovasc Dis 52: pp. 347-61 CrossRef
  11. Macario, AJ, Conway de Macario, E (2002) Sick chaperones and ageing: a perspective. Ageing Res Rev 1: pp. 295-311 CrossRef
  12. Berk, JL, Suhr, OB, Obici, L (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310: pp. 2658-67
  13. Coelho, T, Maia, LF, Martins da Silva, A (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79: pp. 785-92 CrossRef
  14. Sah D. Phase I safety, pharmacokinetic and pharmacodynamics results for ALN-TTR01, a novel RNAi therapeutic for the treatment of transthyretin amyloidosis. VIIIth International Symposium on Familial Amyloid Polyneuropathy. 2011.
  15. Benson, MD, Pandey, S, Witchell, D (2011) Antisense oligonucleotide therapy for TTR amyloidosis. Amyloid 18: pp. 60 CrossRef
  16. Coelho, T, Adams, D, Silva, A (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369: pp. 819-29 CrossRef
  17. Perugini, E, Guidalotti, PL, Salvi, F (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46: pp. 1076-84 CrossRef
  18. Quarta, CC, Guidalotti, PL, Longhi, S (2012) Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc Imaging 5: pp. 755-8 CrossRef
  19. Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38(3):470鈥?. / This is the largest trial validating the role of ^{/ 99m} / Tc-DPD in cardiac amyloid imaging. Although with less accuracy than previously thought, ^{/ 99m} / Tc-DPD can detect a cardiac amyloid with overall good sensitivity and specificity.
  20. Kristen AV, Haufe S, Schonland SO, et al. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol. 2011.
  21. Wizenberg, TA, Muz, J, Sohn, YH (1982) Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the non-invasive diagnosis of cardiac amyloidosis. Am Heart J 103: pp. 468-73 CrossRef
  22. Gertz, MA, Brown, ML, Hauser, MF, Kyle, RA (1987) Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med 147: pp. 1039-44 CrossRef
  23. Yamamoto, Y, Onoguchi, M, Haramoto, M (2012) Novel method for quantitative evaluation of cardiac amyloidosis using (201)TlCl and (99m)Tc-PYP SPECT. Ann Nucl Med 26: pp. 634-43 CrossRef
  24. Bokhari S, Casta帽o A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195鈥?01. / This is the first trial using an objective quantitative method for distinguishing ATTR from AL. ^{/ 99m} / Tc-PYP is widely available in the USA and was found to have good sensitivity and specificity for identifying ATTR.
  25. Nakata, T, Shimamoto, K, Yonekura, S (1995) Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: detection with iodine-12-MIBG. J Nucl Med 36: pp. 1040-2
  26. Arbab, AS, Koizumi, K, Toyama, K (1997) Scan findings of various myocardial SPECT agents in a case of amyloid polyneuropathy with suspected myocardial involvement. Ann Nucl Med 11: pp. 139-41 CrossRef
  27. Tanaka, M, Hongo, M, Kinoshita, O (1997) Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol 29: pp. 168-74 CrossRef
  28. Delahaye, N, Dinanian, S, Slama, MS (1999) Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Eur J Nucl Med 26: pp. 416-24 CrossRef
  29. Hongo, M, Urushibata, K, Kai, R (2002) Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 144: pp. 122-9 CrossRef
  30. Noordzij W, Glaudemans AW, Rheenen RW, et al. (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging. 2012;39(10):1609鈥?7. / This trial demonstrates the potential of ^{/ 123} / I-MIBG in detecting early cardiac amyloid, specifically in patients with ATTRm. This will be important with the emergence of new pharmacotherapies available for cardiac amyloid.
  31. Delahaye, N, Rouzet, F, Sarda, L (2006) Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Med (Baltimore) 85: pp. 229-38 CrossRef
  32. Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2012.
  33. Wall, JS, Kennel, SJ, Stuckey, AC (2010) Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 116: pp. 2241-4 CrossRef
  34. Wong, DF, Rosenberg, PB, Zhou, Y (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F18). J Nucl Med 51: pp. 913-20 CrossRef
  35. Cueto-Garcia, L, Tajik, AJ, Kyle, RA (1984) Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc 59: pp. 589-97 CrossRef
  36. Falk, RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112: pp. 2047-60 CrossRef
  37. Sun, JP, Stewart, WJ, Yang, XS (2009) Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 103: pp. 411-5 CrossRef
  38. Penugonda, N (2010) Cardiac MRI in infiltrative disorders: a concise review. Curr Cardiol Rev 6: pp. 134-6 CrossRef
  39. Kwong, RY, Falk, RH (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111: pp. 122-4 CrossRef
  40. Karamitsos, TD, Piechnik, SK, Banypersad, SM (2013) Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 6: pp. 488-97 CrossRef
  
• 刊物主题：Cardiology; Imaging / Radiology; Diagnostic Radiology; Interventional Radiology; Ultrasound; Nuclear Medicine;
• 出版者：Springer US
• ISSN：1941-9074

文摘

Amyloidosis is an infiltrative disease caused by the extracellular deposition of misfolded proteins in organs and tissues resulting in progressive functional and structural impairment. Cardiac amyloidosis is a leading cause of morbidity and mortality in primary light-chain amyloid (AL) and transthyretin-related cardiac amyloid (ATTR) and results in a restrictive cardiomyopathy, heart failure, and death. With the emergence of new subtype-specific pharmacological therapies targeting misfolded amyloid fibrils, the need for early recognition of a cardiac amyloid subtype is of major therapeutic and prognostic importance. Recently, nuclear scintigraphy with radioactive bone-seeking tracers has shown promising results in distinguishing ATTR amyloidosis from AL amyloidosis and may potentially be useful in following disease burden. This review begins with an overview of cardiac amyloidosis and then focuses on the current radioactive tracers involved in cardiac amyloid detection and concludes with future outlook.